VolitionRx Reports 40% Revenue Growth in 2025, Secures Key Clinical Orders
Event summary
- VolitionRx reported $1.7M in full-year 2025 revenue, up 40% YoY, with Q4 revenue growth of 133%.
- Secured first order for Nu.Q® Cancer assays for clinical certification in lung cancer.
- Nu.Q® NETs assay included in a $7.3M government-backed sepsis detection program in France.
- Raised $8.3M in post-year-end funding, including $5.4M from equity sales and $1M in non-dilutive funding.
- Operating expenses down 17% YoY, net loss reduced by 14%, and net cash used in operations down 24%.
The big picture
VolitionRx's 2025 results highlight its progress in commercializing epigenetic diagnostic tests, with key milestones in lung cancer and sepsis detection. The company's ability to secure licensing deals and maintain financial discipline will be critical as it competes in the rapidly evolving diagnostics market. The $7.3M French sepsis program and discussions with top diagnostic firms underscore the strategic importance of its Nu.Q® platform.
What we're watching
- Licensing Momentum
- Whether VolitionRx can convert discussions with 10 leading diagnostic companies into licensing deals.
- Clinical Validation
- The pace at which Nu.Q® assays gain real-world clinical adoption in cancer and sepsis detection.
- Financial Sustainability
- How long VolitionRx can sustain reduced operating expenses while scaling revenue growth.
Related topics